Venlafaxine versus other anti-depressive agents for depression

Andrea Cipriani; Alessandra Signoretti; Toshi A Furukawa; Rachel Churchill; Silva Tomelleri; Ichiro M Omori; Hugh McGuire; Corrado Barbui

doi:10.1002/14651858.CD006530

Venlafaxine versus other anti-depressive agents for depression

Cochrane Database Syst Rev. 2007:(2):CD006530. doi: 10.1002/14651858.CD006530.

Authors

Andrea Cipriani¹, Alessandra Signoretti¹, Toshi A Furukawa², Rachel Churchill³, Silva Tomelleri⁴, Ichiro M Omori⁵, Hugh McGuire⁶, Corrado Barbui¹

Affiliations

¹ Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy.
² Department of Psychiatry & Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
³ Academic Unit of Psychiatry, Community Based Medicine, University of Bristol, Bristol, UK.
⁴ Department of Medicine and Public Health, Section of Psychiatry, University of Verona, Verona, Italy.
⁵ Cochrane Schizophrenia Group, University of Nottingham, Nottingham, UK.
⁶ National Coordinating Centre for Women and Child Health, London, UK.

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the efficacy of venlafaxine in comparison with other anti-depressive agents in alleviating the acute symptoms of major depressive disorder.To review acceptability of treatment with venlafaxine in comparison with other anti-depressive agents.To investigate the adverse effects of venlafaxine in comparison with other anti-depressive agents.